Heart rebuilt with stem cells learns to beat again


Mouse heart muscle precursor cells created from embryonic stem cells at the Gladstone Institutes in the lab of Bruce Conklin.

The past few months we have written about two themes emerging in stem cell science: neighborhood matters when you want to get a stem cell to grow up into a functional adult; and the best cell to get the job done is often a “middleman,” a cell that is part of the way down the path from stem cell to functional adult tissue called a precursor cell.

Now a team from the University of Pittsburgh has used cells they describe as multipotential cardiovascular progenitors (MCP) to rebuild a mouse heart. They called them “multipotential” because they could form all three types of cells found in the adult heart. They placed these middleman cells on the scaffold of a mouse heart that was left over after they used chemicals to remove all the living cells. That framework provided the neighborhood necessary to tell the MCPs to become the three different cells in the right places.

The researchers started with a human skin sample and reprogrammed those cells into the iPS type of stem cell. They then used various genetic factors to get them to mature to the point of being MCPs.

The team published the research in Nature Communication and a news website wrote this story from the University’s press release. It quotes the senior researcher, Lei Yang, on both the importance of the middleman cell and the scaffold as a neighborhood:

“This process makes MCPs, which are precursor cells that can further differentiate into three kinds of cells the heart uses, including cardiomyocytes, endothelial cells and smooth muscle cells. Nobody has tried using these MCPs for heart regeneration before. It turns out that the heart’s extracellular matrix — the material that is the substrate of heart scaffold — can send signals to guide the MCPs into becoming the specialized cells that are needed for proper heart function.” 

After a few weeks in the lab the heart began to beat, but at a slower rate than either a human or mouse heart, just 40 to 50 beats a minute. Before this technology could be considered for human heart transplants the new heart would need to be made stronger and researchers would need to figure out how to also rebuild the heart’s electrical system that tells the organ to speed up or slow down.

But the team’s immediate goal is to use MCPs and smaller scaffolds to make patches of heart muscle to mend small areas damaged by a heart attack.

Other teams are using stem cells to deliver protein factors to damaged hearts that can signal our body’s naturally occurring healing mechanisms to do a better job. CIRM funds several teams working a mending broken hearts, You can read about that work here.

Don Gibbons

Advertisements

One thought on “Heart rebuilt with stem cells learns to beat again

  1. Gene Breakthroughs Spark a Revolution in Cancer Treatment

    The newfound variants have led major cancer centers to revamp their approach to treating cancer and have spurred a rush among drug companies to find medicines that narrowly target each one.

    The drugs don't cure cancer and face significant hurdles. But doctors now talk of a “precision medicine” approach in which those pinpoint drugs can treat tumors far more effectively than catchall chemotherapy.

    “What we're seeing is the beginning of a revolution in therapeutics,” says Janet Woodcock, director of the Food and Drug Administration's Center for Drug Evaluation and Research. “We can only hope that this gets us to where cancer is managed or curable.”

    Among signs that revolution really is afoot: A June 2013 study found that lung-cancer patients who were treated with drugs targeted at their genetically identified varieties lived 1.4 years longer than patients on chemotherapy whose cancers weren't genetically identified.

    In effect, lung cancer is no longer a few common diagnoses. Instead, it is a growing list of rare cancers, each a target for its own drug regimen.

    “It's likely that more than half of tumors have some alteration we can target with a drug,” says John V. Heymach, a lung-cancer specialist at MD Anderson Cancer Center, Houston. “They may not all have the same success, but we know that in many cases, a targeted agent will work very well.”

    The same goes for other malignancies: Scientists have decoded tumor DNA from breast, colon, kidney, skin and other cancers in recent years to discover scores of variations they didn't know existed before.

    In 2010, precision medicine was still so nascent that Ms. Carey had to show unusual persistence. Few doctors even considered testing tumors for mutations.

    She says she had to demand the test. “Are you helping to save my life,” she recalls asking her doctor at the time, “or just waiting for me to die?”
    http://online.wsj.com/article/SB10001424127887323300004578557473861805376.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s